You are here

FDA Approves Bio Products Laboratory’s Gammaplex 10% for Treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura

February 7, 2017

CLICK HERE to read the press release from Bio Products Laboratory Limited (BPL) regarding the recent FDA approval of Gammaplex® 10%.

News Category: